经肝动脉放疗性栓塞治疗肝癌的研究进展

PDF (PC)

Like

Knowledge

Progress research on transarterial radioembolization in treatment of hepatocellular carcinoma

Metrics

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 10

doi:10.13481/j.1671-587x.20160341

[1] TorreLA,Bray F,Siegel RL.Global cancer statistics 2012[J].CA Cancer J Clin,2015,65(2):87-108.

[2] Villanueva A,Llovet JM.Liver cancer in 2013:Mutational landscape of HCC-the end of the beginning[J].Nat Rev Clin Oncol,2014,11 (2):73-74.

[3] Willatt J,Hannawa KK,Ruma JA.Image-guided therapies in the treatment of hepatocellular carcinoma:A multidisciplinary perspective[J].World J Hepatol,2015,7(2):235-244.

[4] Ni JY,Xu LF,Wang WD,et al.Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma:a meta-analysis[J].World J Gastroenterol,2014,20 (45):17206-17217.

[5] Hawkins MA,Dawson LA.Radiation therapy for heapatocellular carcinoma[J].Cancer,2006,106(8):1653-1663.

[6] Zeng ZC,Fan J,Tang ZY,et al.A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus[J].Int J Radiat Oncol Biol Phys,2005,61(2):432-443.

[7] Lambert B,VandeWiele C.Treatment of hepatocellular carcinoma by means of radiopharmaceuticals [J].Eur J Nucl Med Mol Imaging,2005,32(8):980-989.

[8] Ariel IM,Pack GT.Treatment of inoperable cancer of the liver by intra-arterial radioactive isotopes and chemotherapy[J].Cancer,1967,20(5):793-804.

[9] Blanchard RJ,Grotenhuis I,Lafave JW,et al.Treatment of experimental tumors; utilization of radioactive microspheres[J].Arch Surg,1964, 89:406-410.

[10] NeffR,Abdel-Misih R,Khatri J,et al.The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors[J].Cancer Invest, 2008,26(2):173-177.

[11] Yan ZP,Lin G,Zhao HY,et al.An experimental study and clinical pilot trials on yttrium-90 glass microspheres through the hepatic artery for treatment of primary liver cancer[J].Cancer,1993,72(11):3210-3215.

[12] Sacco R,Mismas V,Marceglia S.Transarterial radioembolization for hepatocellular carcinoma:An update and perspectives[J].World J Gastroenterol,2015,21 (21):6518-6825.

[13] Riaz A,Awais R,Salem R.Side effects of yttrium-90 radioembolization[J].Front Onol,2014.doi:10.3389/fonc.2014.00198.

[14] Sangro B,Iarrairaegui L,Bilbao JI.Radioembolization for hepatocellular carcinoma[J].J Hepatol, 2012,56(2):464-473.

[15] Lewandowski RJ,Kulik LM,Riaz A,et al.A comparative analysis of transarterial downstaging for hepatocellular carcinoma:chemoembolization versus radioembolization[J].Am J Transplant,2009,9(8):1920-1928.

[16] She WH,Cheung TT,Yau TC,et al.Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection[J].Hepatobiliary Surg Nutr,2014,3 (4):185-193.

[17] Vouche M,Kulik L,Atassi R,et al.Radiological-pathological analysis of WHO,RECIST,EASL,mRECIST and DWI:Imaging analysis from a prospective randomized trial of Y90 ± sorafenib[J].Hepatology,2013,58 (5):1655-1666.

[18] Kulik L,Vouche M,Koppe S, et al.Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma[J].J Hepatol,2014,61 (2):309-317.

[19] Fujiki M,Aucejo F,Choi M,et al.Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation:where do we stand?[J]. World J Gastroenterol,2014,20 (18):5308-5319.

[20] Mazzaferro V,Sposito C,Bhoori S,et al.Yttrium-9 radioembolization for intermediate-advanced hepatocellular carcinoma:a phase 2 study[J].Hepatology,2013,57(5):1826-1837.

[21] Hilgard P,Hamami M,Fouly AE,et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma:European experience on safety and long-term survival[J].Hepatology,2010,52 (5):1741-1749.

[22] Salem R,Lewandowski RJ,Mulcahy MF,et al.Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres:a comprehensive report of long-term outcomes[J].Gastroenterology,2010,138 (1):52-64.

[23] Liu D,Fong DY,Chan AC,et al.Hepatocellular carcinoma:surveillance CT schedule after hepatectomy based on risk stratification[J].Radiology,2015,274(1):133-140.

[24] Crissien AM,Frenette C.Current management of hepatocellular carcinoma[J].Gastroenterol Hepatol,2014,10(3):153-161.

[25] Bruix J,Gores GJ,Mazzaferro V.Hepatocellular carcinoma:clinical frontiers and perspectives[J].Gut,2014,63(5):844-855.

[26] Woo HY,Heo J.New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis[J].Clin Molecul Hepatol,2015,21 (2 ):115-121.

[27] Lambert B,Sturm E,Mertens J,et al.Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma:4 years experience at the Ghent University Hospital[J].Eur J Nucl Med Mol Imaging,2011,38(12):2117-2124.

[28] Strigari L,Sciuto R,Rea S,et al.Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres:radiobiologic considerations[J].J Nucl Med,2010,51(9):1377-1385.

[29] Andreana L,Isgro G,Marelli L,et al.Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds:Trans-arterial radio-embolisation of HCC[J].Cancer Treat Rev,2012,38 (6):641-649.

[30] 王保信,武振明,张锐,等.联合应用雷替曲塞及表柔比星经肝功脉化疗栓塞术治疗中晚期原发性肝癌的临床观察[J].临床肝胆病杂志,2015,31(5):725-728.

[31] 祝普利,尹超,冯建龙.原发性肝癌综合治疗进展[J].临床肝胆病杂志,2015,31(6):965-968.

Viewed

Full text

From	Others	local

Times	6	61
Rate	9%	91%

Abstract

443

Just accepted	Online first	Issue

0	0	443

From	Others	local

Times	442	1
Rate	100%	0%

Cited

Web of Science	Crossref	ScienceDirect	Search for Citations in Google Scholar >>


This page requires you have already subscribed to WoS.

Shared

Just accepted

Online first

Just accepted

Online first

[1]	Runhong MU, Xinzhu LIU, Rui LIN, Yupeng LI, Luyao WANG, Chunyu WANG, Xiao GUO. Effect of PRDX6 over-expression of proliferation, invasion and migration of liver cancer cells and its molecular mechanism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 559-565.
[2]	CHEN Xi, BAI Lin, WANG Yingying, CAO Shuang, MU Hongping, WANG Yilin, SHI Hao, ZHANG Qian, GAO Xin, ZHANG Chengyi, ZHANG Ruowen. Inhibitory effect of tanshinone ⅡA on proliferation and migration of human liver cancer HepG2 cells and its apoptosis-promoting effect [J]. Journal of Jilin University(Medicine Edition), 2019, 45(03): 531-538.
[3]	XU Zhenhua, SU Rongjian. Inhibitory effects of zingerone combined with sorafenib on migration and invasion of human liver cancer HepG2 cells [J]. Journal of Jilin University(Medicine Edition), 2019, 45(02): 228-233.
[4]	YU Tao, JIAO Xue, FU Changfeng, LI Qin. Selective effects of cyclamin on proliferation and apoptosis of liver cancer cells and their mechanisms [J]. Journal of Jilin University(Medicine Edition), 2019, 45(02): 319-324.
[5]	MIAO Xiangxia, GUO Rui, ZHANG Ying, WEI Yinyin, LUO Zhengqi, MIN Yali, LIU Kaige. Inhibitory effect of resveratrol on fat synthesis in liver cancer HepG₂ cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2019, 45(01): 69-72.
[6]	GU Teng, WANG Jiang, CHEN Xiaoqian, LIU Kai. Hepatic angiomyolipoma: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2019, 45(01): 153-155.
[7]	ZHU Deqiang, CHEN Xuejun. Effects of plumbagin on proliferation and apoptosis of hepatocellular carcinoma HepG2R cells resistant to sorafenib and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1223-1229.
[8]	LI Tianzhu, WANG Jiaru, ZHANG Junyi, WANG Hongquan, SHI Tiewei, ZHOU Jing, BAI Chunying, JIN Chenghao. Expression of ELK-3 protein in hepatocellular carcinoma tissue and its effects on migration and invasion abilities of HepG2 cells [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 736-740.
[9]	ZHENG Yan, WANG Na, WU Mingkun, LIU Jingqiao, MENG Yali. Influence of mifepristone in expression levels of Ang-1,Ang-2, VEGF, TNF-α and IL-6 in serum and villus tissue of patients with missed abortion [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 791-795.
[10]	LIU Xia, QI Fengjie, DU Xiaoyuan. Effects of silencing expression of CRAF gene on invasion and metastasis of hepatocellular carcinoma cells [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 521-525.
[11]	XING Shaoji, ZHENG Liansheng, WANG Diandong, ZHANG Xuan, CHI Min. Analysis on association between single nucleotide polymorphism of selenoprotein S gene and risk of liver cancer [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 558-562.
[12]	YANG Li, WANG Xuewen, ZHOU Ming, ZHANG Fan. Effect of arsenic trioxide combined with γ-secretase inhibitor MW167 on drug resistance of human hepatocellular carcinoma HepG₂/ADM cells [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 1-7.
[13]	SU Han, ZHANG Meijia, WANG Huaijie, LI Na, HUO Lianguang, LI Guizhi, DAI Gong, GAO Zhiqin, YANG Xiaoyun, QU Meihua. Effects of Exendin-4 on expressions of lipid metabolism related genes in HepG₂ cells with insulin resistance [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 36-40.
[14]	YU Lei, WANG Zhicheng, WANG Tiejun. Inhibitory effect of caffeine combined with ionizing radiation on proliferation of hepatocellular carcinoma stem cells silenced by Chk-1 and its apoptosis-induced effect [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 52-57.
[15]	WANG Jianfeng, FANG Fang, YU Lei, WANG Zhicheng. Effects of Xiaoaiping combined with X-rays radiation on proliferation and apoptosis of human liver cancer HepG₂ cells [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 73-77.